Oxford Biomedica
Total Voting Rights
Oxford, UK - 02 September 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or
"the Company"), a quality and innovation-led cell
and gene therapy CDMO, today announces
that in accordance with the FCA's
Disclosure Guidance and Transparency Rule 5.6.1R, the Company's
issued share capital as at the close of business on 31 August 2024
consisted of 105,341,569 ordinary
shares of 50 pence each ("Ordinary Shares"). There are no Ordinary
Shares held in treasury.
Accordingly, the total number of
voting rights in Oxford Biomedica at the date of this notice
is 105,341,569.
The above figure 105,341,569 may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, Oxford Biomedica under the FCA's Disclosure
Guidance and Transparency Rules.
-Ends-
|
For further
information, please contact:
|
|
|
Oxford
Biomedica plc:
Natalie Walter, Company Secretary
|
Tel: +44 (0)1865 783 000
|
ABOUT OXFORD
BIOMEDICA
Oxford Biomedica (LSE: OXB) is a quality and
innovation-led contract development and manufacturing organisation
(CDMO) in cell and gene therapy with a mission to enable its
clients to deliver life changing therapies to patients around the
world.
One of the original pioneers in cell and gene
therapy, OXB has more than 25 years of experience in viral vectors;
the driving force behind the majority of cell and gene therapies.
OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV), adenovirus, and other viral vector
types. Oxford Biomedica's world-class capabilities span from
early-stage development to commercialisation. These capabilities
are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.
OXB offers a vast number of unique technologies
for viral vector manufacturing, including a 4th generation
lentiviral vector system (the TetravectaTM system), dual plasmid
system for AAV production, suspension and perfusion process using
process enhancers and stable producer and packaging cell
lines.
Oxford Biomedica, a FTSE4Good constituent, is
headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK,
Lyon and Strasbourg, France, and near Boston, MA, US. Learn
more at www.oxb.com, and follow us on LinkedIn
and YouTube.